Jasper Therapeutics has completed the enrollment of the first IgAN cohort of its Phase 2 study evaluating vensobafusp alfa. The company anticipates reporting initial interim data by year-end 2026 and plans to accelerate an expansion cohort in FSGS patients in early 2027.